KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Debt (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Non-Current Debt for 5 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 1.08% to $9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2025, down 1.08% year-over-year, with the annual reading at $9.6 million for FY2025, 1.08% down from the prior year.
  • Non-Current Debt hit $9.6 million in Q4 2025 for Castle Biosciences, down from $10.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $10.0 million in Q3 2025 to a low of $8.1 million in Q2 2025.